Connect with us

Health

Diabetes and weight-loss drug ‘changed my life,’ says senator: ‘I feel a decade younger’

Published

on

Diabetes and weight-loss drug ‘changed my life,’ says senator: ‘I feel a decade younger’

A U.S. senator said a GLP-1 drug changed his life — and now he’s calling for widespread access to anti-obesity medications.

In a New York Times op-ed on April 8, Sen. John Fetterman, D-Pa., wrote about his experience with Mounjaro (tirzepatide).

The injectable prescription medicine is primarily used to treat type 2 diabetes. 

OZEMPIC’S HEALTH BENEFITS KEEP GROWING, BUT ARE THE RISKS WORTH IT?

Fetterman was prescribed the medication in July 2024.

Advertisement

“As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote.

Sen. John Fetterman, D-Pa., walks to the chamber on Capitol Hill in Washington, D.C., on March 14, 2025. In an op-ed on April 8, the Pennsylvania senator wrote about his experience with Mounjaro (tirzepatide). (Reuters)

“Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board. It’s made a significant impact on my overall health,” he continued. 

“Aches, pains and stiffness have vanished. Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years. As far as side effects, I’ve also lost around 20 pounds.”

GENETIC CHOLESTEROL ELIMINATED BY NEW DRUG, REDUCING HEART ATTACK RISK, STUDY FINDS

Advertisement

Beyond lowering blood sugar, GLP-1 medications have also been linked to a range of other benefits, including improved heart health, neurological function and metabolic health, as Fox News Digital has reported.

Eli Lilly, maker of Mounjaro, also offers another version of the drug called Zepbound, which is the same medication approved for weight loss, chronic weight management and sleep apnea. 

Other GLP-1 medications include Ozempic, Wegovy, Victoza, Saxenda, all made by Novo Nordisk.

Sen. Fetterman is pictured at the White House on Jan. 29, 2025. “As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote in an April op-ed. (Reuters)

Fetterman noted that GLP-1 drugs have been found to have beneficial effects on cholesterol, heart rate and heart inflammation. 

Advertisement

“Some recent studies suggest they might even help curb alcohol addiction and support cognitive function, potentially slowing or preventing conditions like Parkinson’s and Alzheimer’s,” he wrote in the Times op-ed.

“Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years.”

In the op-ed, Fetterman called for expanded access to these medications, which can cost up to $1,000 out of pocket if not covered by insurance.

“Currently, Medicare covers these drugs only under specific circumstances, such as for diabetes or heightened heart risk,” he wrote. “And Medicaid coverage is even more limited.”

Fetterman added that he was not compensated for sharing his experience.

Advertisement

OZEMPIC ‘MICRODOSING’ IS THE NEW WEIGHT-LOSS TREND

“I’m just a guy who has benefited from these medications and wants to make sure that anyone else who could benefit from them can have access to them, too,” he wrote.

While Fetterman shares HHS Sec. Robert F. Kennedy Jr.’s views of prioritizing nutrition and healthy living, he said he believes the medications are necessary for some.

Eli Lilly, maker of Mounjaro, also offers another version of the drug called Zepbound, which is the same medication approved for weight loss, chronic weight management and sleep apnea.  (iStock)

“I fully agree that diet and lifestyle matter — a lot. But diet alone isn’t enough,” he wrote. 

Advertisement

“For the millions of Americans struggling with serious health issues, medication can be a crucial first step to regaining enough control of their health to begin making meaningful lifestyle changes.”

Doctors discuss benefits and access

Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News’ senior medical analyst, noted that semaglutides, including Ozempic and Wegovy, are “very important drugs” for type 2 diabetes, with increasing use for obesity. 

“Though these drugs appear to have beneficial uses for the heart and lipid profile — and also the brain and decreasing dementia risk — studies are ongoing and more data is still needed,” he told Fox News Digital.

The first approach to obesity is lifestyle changes, including exercise, improved diet and optimal sleep, Siegel said.

“Having said that, these weight-loss drugs (including Zepbound) are also good tools when lifestyle is not enough,” he noted. 

Advertisement

Fetterman was prescribed Mounjaro for potential heart health benefits. (Getty Images)

“They help prevent down-the-line diseases such as heart disease, stroke, high blood pressure and sleep apnea, which tend to come from obesity.”

He added, “Overall, we are saving the healthcare system money, so I would like to see Medicare and Medicaid approve them for diabetes and weight loss.”

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Dr. Brett Osborn, a Florida neurologist and longevity expert, said he’s been prescribing GLP-1s to his patients since 2019.

Advertisement

“Mounjaro and its cousins aren’t just weight-loss tools — they’re metabolic reset buttons,” he told Fox News Digital.

Beyond lowering blood sugar, GLP-1 medications have also been linked to a range of other benefits, including improved heart health, neurological function and metabolic health. (iStock)

“People with metabolic syndrome don’t need lectures on kale and the importance of exercise. They need help.” 

Osborn agreed that lifestyle is essential, but is “rarely sufficient.”

“GLP-1s give patients momentum by getting the ball rolling,” he said. “And when that happens, health habits are formed. Diet improves. Movement improves. People start to feel the benefits of healthy living.”

Advertisement

For more Health articles, visit www.foxnews.com/health

Osborn noted that these medications aren’t cosmetic, but therapeutic. 

“I’ve seen what they can do firsthand: reductions in body fat, inflammation, glucose, triglycerides and insulin resistance — and with those, significant reductions in the incidence of stroke and heart attack.”

“I believe this is a signal aimed squarely at Big Pharma.”

President Donald Trump’s administration recently announced that Medicare and Medicaid would not cover the medications, as the Centers for Medicare and Medicaid Services said late Friday.

Advertisement

Osborn said the move to block coverage likely doesn’t have to do with efficacy.

“Trump knows these medications work,” Osborn said. “I believe this is a signal aimed squarely at Big Pharma: ‘Lower the price, or Medicare, the biggest buyer on the block, is out.’”

“This isn’t a dismissal — it’s leverage,” Osborn said, stating his opinion on the matter. “President Trump will likely negotiate until the ‘price is right,’ disempowering Big Pharma while concomitantly bettering the health of Americans.”

Fox News Digital reached out to Fetterman’s office for comment.

Advertisement

Health

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier

Published

on

Goodbye, Late-Night Cravings! How To Curb Hunger and Make Weight Loss Easier


Advertisement





How To Curb Late-Night Cravings and Make Weight Loss Easier | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Health

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

Published

on

Lurking dementia risk exposed by breakthrough test 25 years before symptoms

NEWYou can now listen to Fox News articles!

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge.

Advertisement

That’s according to new research from the University of California San Diego, which found that a specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk.

The researchers analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study in the late 1990s, according to the study’s press release. 

KEY FITNESS MEASURE IS STRONG PREDICTOR OF LONGEVITY AFTER CERTAIN AGE, STUDY FINDS

The women ranged from 65 to 79 years of age and showed no signs of cognitive decline at the start of the study.

After tracking the participants for up to 25 years, the researchers concluded that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with future mild cognitive impairment and dementia. 

Advertisement

A new blood test could determine a woman’s dementia risk as early as 25 years before symptoms emerge. (iStock)

Women who had higher levels of p-tau217 at the beginning of the study were “much more likely” to develop the disease. The findings were published today in JAMA Network Open.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” first author Aladdin H. Shadyab, a UC San Diego associate professor of public health and medicine, told Fox News Digital. 

“These biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia.”

“Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin,” he added.

Advertisement

This long lead time could open the door to earlier prevention strategies and more targeted monitoring, rather than waiting until memory problems are already affecting daily life, according to Shadyab.

A specific biomarker protein associated with early pathological processes of Alzheimer’s disease was “strongly linked” to future dementia risk. (iStock)

“As the research advances, these biomarkers may help us identify who is at greatest risk and develop strategies to delay or prevent dementia,” he said.

This risk relationship wasn’t the same across the board, however. Women over 70 with higher p-tau217 levels had “poorer cognitive outcomes” compared to those under 70, as did those with the APOE ε4 gene, which is a known risk factor for Alzheimer’s disease.

Advertisement

The study also found that p-tau217 was a stronger predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy compared to those who received a placebo.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” said senior author Linda K. McEvoy, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, in the release. 

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” a researcher said. (iStock)

“This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Advertisement

Blood tests for Alzheimer’s disease are still being studied and are not recommended for routine screening in people without symptoms, Shadyab noted. 

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

More research is needed before this approach can be considered for clinical use prior to cognitive symptoms. 

Future studies should investigate how other factors — like genetics, hormone therapy and age-related medical conditions — might interact with plasma p-tau217, the researchers added.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

“The study examined only older women, so the findings may not necessarily apply to men or younger populations,” Shadyab noted. “We also examined overall dementia outcomes rather than specific subtypes such as Alzheimer’s disease.”

Continue Reading

Health

Key fitness measure is strong predictor of longevity after certain age, study finds

Published

on

Key fitness measure is strong predictor of longevity after certain age, study finds

NEWYou can now listen to Fox News articles!

For women over 60, muscle strength plays a critical role in longevity, a new study confirms.

Researchers at the University at Buffalo, New York, followed more than 5,000 women between the ages of 63 and 99, finding that those with greater muscle strength had a significantly lower risk of death over an eight-year period.

The findings were published in JAMA Network Open.

EXERCISE AFFECTS THE HEART IN A HIDDEN, POWERFUL WAY BY REWIRING NERVES, STUDY FINDS

Advertisement

Muscle function was measured using grip strength and how quickly participants could complete five unassisted sit-to-stand chair raises. 

These are two tests commonly used in clinical settings to evaluate muscle function in older adults, the researchers noted.

A recent study shows that stronger muscle strength in women over 60 is linked to a lower risk of death over eight years. (iStock)

“In a community cohort of ambulatory older women, muscular strength was associated with significantly lower mortality rates, even when we accounted for usual physical activity and sedentary time measured using a wearable monitor, gait speed and blood C-reactive protein levels,” study lead author Michael LaMonte, research professor of epidemiology and environmental health at the University at Buffalo, told Fox News Digital.

“Movement is the key — just move more and sit less.”

Advertisement

Many earlier studies did not include those objective measurements, making it difficult to determine whether muscle strength itself was linked to longevity, according to LaMonte. “Our study was able to better isolate the association between strength and death in later life,” he added.

Even for women who don’t get the recommended amount of aerobic physical activity, which is at least 150 minutes per week, muscle strength remained important for longevity, the researchers found.

Women with greater muscle strength were more likely to live longer, even if they did not meet the recommended amount of aerobic exercise. (iStock)

“The findings of lower mortality in those who had higher strength but were not meeting current national guidelines on aerobic activity were somewhat intriguing,” LaMonte said.

Advertisement

CLICK HERE FOR MORE LIFESTYLE STORIES

Federal guidelines recommend strengthening activities one to two days per week, targeting major muscle groups.

Resistance training does not have to require a gym membership, LaMonte noted. These exercises can be performed using free weights, resistance bands, bodyweight movements or even household items, such as soup cans.

Experts recommend working major muscle groups one or two days a week using weights, bands or bodyweight exercises. (iStock)

“Movement is the key — just move more and sit less,” he said. “When we can no longer get out of the chair and move around, we are in trouble.”

Advertisement

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

LaMonte acknowledged several limitations of the study. The researchers assessed muscle strength in older age but did not explore how earlier levels in adulthood might influence long-term health outcomes.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“We were not able to understand how strength and mortality relate in younger ages,” he said, noting that future research should explore whether building strength earlier could have an even greater impact on longevity.

Advertisement
Continue Reading

Trending